Lasca (Ethinylestradiol, Levonorgestrel)

The ethinylestradiol component provides estrogenic activity while levonorgestrel supplies progestogenic effects. Together they suppress the hypothalamic‑pituitary‑ovarian axis, preventing the mid‑cycle surge of luteinizing hormone that triggers ovulation. They also thicken cervical mucus and alter the endometrial lining, creating an environment that is unfavorable for sperm penetration and implantation.

The specific dosing regimen for Lasca is determined by the prescribing clinician based on the product’s labeling and the patient’s individual health profile. Typically, combined oral contraceptives are taken once daily for a defined cycle, but the exact number of tablets and any hormone‑free interval must be confirmed by a qualified healthcare professional.

Lasca is classified as Pregnancy Category X, indicating that it must not be used during pregnancy because it can cause harm to the developing fetus. Women who are breastfeeding should also consult their healthcare provider, as hormonal contraceptives can affect milk production and infant exposure. Alternative non‑hormonal methods are recommended in these situations.

To place an order, submit an enquiry on the Lasca product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details and any necessary import documentation.

Lasca contains the standard dose combination of ethinylestradiol and levonorgestrel, which is comparable to many other CO‑C pills on the market. Its efficacy, safety profile and side‑effect spectrum are similar to other products that use the same hormone pair, while formulation differences such as tablet size or inactive ingredients may influence tolerability for individual patients.

Lasca tablets should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the medication in its original blister pack or container, protect it from excessive moisture, heat and direct sunlight. Do not store in bathrooms or near kitchen appliances, and keep out of reach of children.

Lasca is taken orally, usually once each day at the same time, following the regimen indicated on the prescribing information (e.g., 21 active tablets followed by a hormone‑free interval). Swallow the tablet whole with water; it may be taken with or without food. Consistent daily intake is essential to maintain contraceptive effectiveness.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, arterial clot formation leading to stroke or myocardial infarction, and severe allergic reactions that may present as anaphylaxis. Women with a history of clotting disorders, uncontrolled hypertension, smoking habit over age 35, or certain liver diseases should be evaluated carefully before use.

Lasca is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or are smokers aged 35 years or older. It should also be avoided in individuals with known hypersensitivity to ethinylestradiol, levonorgestrel or any of the tablet’s excipients. A healthcare professional must assess suitability before prescribing.